

# Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

## CD159c (NKG2C) Antibody, anti-human, PE, REAfinity™

RRID:AB\_2751835

Type: Antibody

---

### Proper Citation

Miltenyi Biotec Cat# 130-119-776, RRID:AB\_2751835

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2751835](http://antibodyregistry.org/AB_2751835)

**Proper Citation:** Miltenyi Biotec Cat# 130-119-776, RRID:AB\_2751835

**Target Antigen:** CD159c (NKG2C)

**Host Organism:** human

**Clonality:** monoclonal

**Comments:** Antigen distribution: NK cells

Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-103-635. (RRID:AB\_2655394).

**Antibody Name:** CD159c (NKG2C) Antibody, anti-human, PE, REAfinity™

**Description:** This monoclonal targets CD159c (NKG2C)

**Target Organism:** human

**Clone ID:** clone REA205

**Antibody ID:** AB\_2751835

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-119-776

**Record Creation Time:** 20250820T031356+0000

**Record Last Update:** 20250820T154152+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD159c (NKG2C) Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD159c (NKG2C) Antibody, anti-human, PE, REAfinity™.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Yang CH, et al. (2026) Peripheral immune landscape in pancreatic ductal adenocarcinoma reveals expansion of effector states with disease progression. iScience, 29(3), 115034.

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell stem cell, 31(9), 1376.

Mathewson ND, et al. (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell, 184(5), 1281.